Stocktoria

OptimizeRx Corp OPRX

Nasdaq · stock · Services-Business Services, NEC · website · IPO 2005-05-18

OptimizeRx Corp (OPRX) earns a Piotroski F-score of 8/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $109.4M at a 4.7% net margin.

Chart by TradingView
75/100
Stocktoria Quality Score · grade A
8/9
Piotroski F — financial health
3.37
Altman Z″ — distress risk · safe
Dividend yield · no dividend
-2.84
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
3 6 3 2 6 4 1 2 5 8 2017201820192020202120222023202320242025
Altman Z″
-6.22 2.06 4.07 5.39 18.48 18.15 1.53 1.48 3.37 2017201820192020202120222023202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$7.04 as of 2026-08-12 · -65.7% 1y
$5.19$20.5052-wk

Beneish M-score: -2.84 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$96M
P / E18.7×
Net margin 5y avg-15%
Return on equity 5y avg-9.1%
Beta1.1
Employees132

Analyst price target

$12.40 +76.1% vs last
consensus: strong buy · 5 analysts
target range $9.00 – $18.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Revenue trend · last 9y · up

How it ranks in Services · percentile among 982 companies

Piotroski Fstronger than 97%
Net marginstronger than 66%
Return on equitystronger than 55%
Revenue growthstronger than 78%

Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 8/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.246
Retained earnings / assets-0.448
EBIT / assets0.066
Equity / liabilities2.638

Sector peers · similar-size Services companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
OPRXOptimizeRx Corp8/93.3718.7+18.8%
BAERBridger Aerospace Group Holdings, Inc.7/924.1+24.6%
NOTEFiscalNote Holdings, Inc.2/9-12.08-20.7%
DHXDHI GROUP, INC.4/9-0.09-9.9%
SGRPSPAR Group, Inc.2/9-4.77-16.8%
PAYSPaysign, Inc.6/91.1460.5+40.5%
POWWOutdoor Holding Co7/96.36+3.5%

All Services companies →

About OptimizeRx Corp

OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

FAQ

Is OPRX financially healthy?

OptimizeRx Corp's Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does OPRX pay a dividend?

No, OptimizeRx Corp does not currently pay a dividend.

How profitable is OPRX?

In FY2025, OptimizeRx Corp had a net margin of 4.7% and a return on equity of 4.0%.

What is OPRX's P/E ratio?

OptimizeRx Corp's trailing price-to-earnings (P/E) ratio is about 18.7×, based on its latest annual earnings.

What is the analyst price target for OPRX?

The average Wall-Street price target for OptimizeRx Corp is $12.40, about 76.1% above the recent price, from 5 analysts (consensus: strong buy).

Is OPRX a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on OptimizeRx Corp: a Piotroski F-score of 8/9, an Altman Z″ in the safe zone, a P/E of about 18.7×. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.